Navigation Links
Golimumab Phase 3 Data Show Significant Improvement In Physical Function In Patients with Rheumatoid Arthritis

Findings Also Showed Patients Experienced Improvements in Quality of Life Measures and Fatigue Despite Treatment with Other Anti-TNFs or Methotrexate

SAN FRANCISCO, Oct. 27 /PRNewswire/ -- Results from two Phase 3 studies showed that patients receiving every four week subcutaneous injections of golimumab (CNTO 148) 50 mg or 100 mg, an investigational therapy, experienced significant improvements in physical function, health-related quality of life (HRQOL) and fatigue. The data from the randomized, double-blind, placebo- controlled studies in patients with active moderate to severe rheumatoid arthritis (RA) were presented at the American College of Rheumatology (ACR) Annual Scientific Meeting. The first trial was in patients who were previously treated with anti-tumor necrosis factor (TNF) agents and the second study was in patients who were active despite ongoing treatment with methotrexate.

"In addition to reducing signs and symptoms, these data show improvement in important measures of functional ability and quality of life," said Jonathan Kay, M.D., Director, Clinical Trials, Rheumatology Unit, Massachusetts General Hospital; Associate Clinical Professor of Medicine, Harvard Medical School, and lead study investigator. "These data support the potential benefit of golimumab in patients previously treated with anti-TNF therapies or methotrexate."

In the study, GOlimumab After Former anti-TNF Therapy Evaluated in RA (GO-AFTER), 50 mg and 100 mg doses of golimumab were studied in patients who had active RA and who were previously treated with anti-TNF treatments, but where anti-TNF treatment had been discontinued due to lack of efficacy (58 percent), intolerance (17 percent) or other reasons (40 percent). Patients continued to receive stable doses of methotrexate, sulfasalazine and/or hydroxychloroquine if they were receiving them at baseline. Golimumab-treated patients who had discontinued previous anti-TNF treatment for any reason experienced significant improvements in physical function, as measured by the Health Assessment Questionnaire (HAQ). HAQ assesses the degree of difficulty a person has in accomplishing tasks in eight functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping and other activities of daily living).

At week 24, the proportion of patients experiencing clinically relevant improvement (increase in HAQ score of at least 0.25 from baseline) was significantly greater for golimumab-treated patients compared with those receiving placebo. More than half of patients in the combined golimumab group (52 percent) achieved the measure, compared with 34 percent of placebo-treated patients (P < 0.001). Also at week 24, patients receiving golimumab experienced a mean improvement in HAQ of 0.27 +/- 0.51, compared with an improvement of 0.05 +/- 0.51 among patients receiving placebo (P < 0.001). Importantly, among patients whose prior anti-TNF therapy was discontinued due to lack of efficacy, golimumab-treated patients experienced a mean improvement of 0.23 +/- 0.50 in HAQ, compared with an average improvement of 0.06 +/- 0.51 for patients receiving placebo (P < 0.05).

At week 24, the combined golimumab group also experienced significantly greater mean improvement in fatigue, 6.8 +/- 11.4, compared with an improvement of 3.0 +/- 9.7 among patients treated with placebo (P < 0.001). Patients were evaluated with the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F), a 13-item questionnaire that assesses self-reported fatigue and its impact on daily activities and function.

Improvements Seen in Patients Previously Treated with Methotrexate

A second Phase 3 study also presented at ACR evaluated 50 mg and 100 mg doses of golimumab in RA patients who had active RA and were previously treated with methotrexate. In GOlimumab FOR subjects With Active RA Despite Methotrexate (GO-FORWARD), patients also indicated significant improvement in fatigue. At week 24, the mean improvement in FACIT-F was 7.2 +/- 8.6 in the combined golimumab group, compared with an improvement of 2.2 +/- 9.5 among patients receiving methotrexate alone (P < 0.001).

According to the Arthritis Foundation, in addition to joint pain and swelling, RA may make daily functioning difficult and is frequently associated with fatigue. "Patients with RA often say that fatigue is one of their most frustrating symptoms because it makes it difficult for them to participate in work or social activities," said Mark Genovese, M.D., professor of medicine at Stanford University School of Medicine, and lead study investigator. "A reduction in fatigue would represent a tremendous benefit and significantly impact the lives of patients with this disease."

Through week 24, patients in both dose groups receiving golimumab plus methotrexate experienced significant improvement in physical function, compared with patients receiving methotrexate alone. At 24 weeks, 70 percent of those receiving golimumab plus methotrexate experienced a clinically relevant improvement in physical function, compared with 39 percent of patients receiving methotrexate alone (P < 0.0001). Also at week 24, the combined golimumab group achieved a mean improvement in HAQ of 0.46 +/- 0.53, compared with an improvement of 0.13 +/- 0.58 among patients receiving methotrexate alone (P < 0.001).

Patients treated with golimumab also experienced significant improvement in HRQOL, as assessed by the Physical Component Summary (PCS) and Mental Component Summary (MCS) scores of the Short form (SF)-36 questionnaire. In the combined golimumab plus methotrexate group, the mean improvement in PCS at week 14 was 7.7 +/- 8.1, compared with an improvement of 2.5 +/- 8.1 in the group receiving methotrexate alone (P < 0.001). Patients in the combined group also experienced a mean improvement in MCS of 3.1 +/- 10.8 at week 24, compared with 0.8 +/- 9.7 among patients receiving methotrexate alone (P < 0.05). The SF-36 is a 36-item questionnaire that assesses impact in eight areas: physical functioning, pain, vitality, social functioning, psychological functioning, general health perceptions and role limitations due to physical and emotional problems. Lower scores indicate poorer functioning and well- being.

The Biologics License Application (BLA) and Marketing Authorization Application (MAA) for golimumab were submitted earlier in the year and are currently under review by the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMEA), respectively. The filings are based on the extensive clinical development program for golimumab, including data from five pivotal Phase 3 trials in RA, psoriatic arthritis and ankylosing spondylitis.

About the GO-AFTER Trial

GO-AFTER was a Phase 3, multi-center, double-blind trial that included 461 patients with active RA of 8.65 years mean duration. All patients had previously received at least one anti-TNF agent, with 25 percent (n=115) having been treated with two therapies and 9 percent (n=43) with three. Discontinuation of previous anti-TNF therapy was due to lack of efficacy (58 percent), intolerance (17 percent) and other reasons (40 percent). Patients were randomized to one of three treatment groups: subcutaneous placebo, golimumab 50 mg or golimumab 100 mg every four weeks. At baseline, 66 percent of patients were receiving methotrexate; 5 percent and 7 percent of patients were receiving sulfasalazine and hydroxychloroquine, respectively. Patients continued to receive stable doses of methotrexate, sulfasalazine and/or hydroxychloroquine if receiving them at baseline.

Golimumab was generally well tolerated in this study. Through week 24, 72 percent, 66 percent and 78 percent of patients in the placebo, golimumab 50 mg and golimumab 100 mg groups, respectively, experienced at least one adverse event (AE). Ten percent of patients in the placebo group experienced serious AEs, compared with 7 percent and 5 percent of patients in the golimumab 50 mg and golimumab 100 mg groups, respectively. Serious infections were reported in 3 percent, 3 percent and 1 percent of patients, and injection site reactions (ISR) through week 16 occurred in 3 percent, 4 percent and 11 percent of patients in the placebo, golimumab 50 mg and golimumab 100 mg groups, respectively. The most commonly reported ISR was erythema, a redness of the skin due to inflammation. No serious or severe ISRs were reported, and none led to the discontinuation of patients in the study. Antibodies to golimumab were detected in 4 percent of golimumab-treated patients (50 mg and 100 mg).

About the GO-FORWARD Trial

GO-FORWARD, a Phase 3, multi-center clinical trial included 444 patients with active RA. Adult patients with more than four tender and swollen joints, despite methotrexate therapy, were randomly assigned to receive golimumab (50 or 100 mg) plus methotrexate, golimumab 100 mg plus placebo or placebo plus methotrexate at weeks 0, 4, 8, 12, 16 and 20. Data were assessed at weeks 14 and 24. The co-primary endpoints were percentage of patients achieving ACR 20 response at week 14 and improvement from baseline in HAQ at week 24.

Through week 24, 68 percent of patients in both the combined golimumab plus methotrexate groups and the placebo plus methotrexate group experienced at least one AE. Nine percent of patients in the combined golimumab plus methotrexate groups experienced a serious AE compared with 4 percent of patients receiving placebo plus methotrexate. Three percent of patients in the combined golimumab plus methotrexate groups and 1 percent in the group receiving placebo plus methotrexate experienced serious infections. Rates of ISRs were 5 percent in the combined golimumab plus methotrexate groups and 3 percent in the group receiving placebo plus methotrexate. Two percent of golimumab-treated patients developed antibodies. Four patients participating in the study developed malignancies: one patient taking golimumab 100 mg plus methotrexate developed breast cancer, one patient taking placebo plus methotrexate developed Bowen's disease and squamous cell skin cancer, one patient taking golimumab 100 mg plus placebo developed basal cell cancer, and one patient taking golimumab 100 mg plus placebo developed squamous cell carcinoma. One patient receiving golimumab 100 mg plus placebo died from diarrhea, colitis and sepsis.

Anti-TNF therapies have been associated with serious and sometimes fatal risks including the risk of tuberculosis and other serious infections, malignancies, heart failure, central nervous system disorders, reactivation of hepatitis B and other serious events.

About Rheumatoid Arthritis

RA is a chronic and debilitating disease that affects approximately 1.3 million people in the United States and more than three million people in Europe. Signs and symptoms of RA include pain, stiffness and motion restriction in multiple joints. Because RA is a progressive disease, it can cause permanent joint deformity and severe disability if not diagnosed early or if initial treatment is delayed. RA can occur at any age, but is most common in adults 30-50 years old and is two-to-three times more prevalent in women than in men. The cause of RA is unknown, although genetic factors may contribute to the disease.

About Golimumab

Golimumab, the next-generation human anti-TNF-alpha monoclonal antibody from Centocor Inc. and Schering-Plough Corporation, is currently in the most comprehensive Phase 3 development program to date for an anti-TNF-alpha biologic therapy. With ongoing studies for the treatment of RA, including a study in a methotrexate-naive patient population, psoriatic arthritis and ankylosing spondylitis, golimumab is being studied as an every four-week subcutaneous injection and an intravenous (IV) infusion therapy. Golimumab targets and neutralizes both the soluble and membrane-bound forms of TNF- alpha.

Centocor discovered golimumab and has exclusive marketing rights to the product in the United States. Pending regulatory approval, Schering-Plough will assume exclusive marketing rights outside the United States except in Japan, Indonesia and Taiwan where golimumab will be co-marketed by Mitsubishi Tanabe Pharma Corporation and Janssen Pharmaceutical Kabushiki Kaisha; Hong Kong, where golimumab will be exclusively marketed by Janssen-Cilag; and China where golimumab will be exclusively marketed by Xian-Janssen.

About Centocor

Centocor is harnessing the power of world-leading research and biomanufacturing to deliver innovative biomedicines that transform patients' lives. Centocor has already brought innovation to the treatment of Crohn's disease, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, ulcerative colitis, pediatric Crohn's disease and psoriasis.

The world leader in monoclonal antibody production and technology, Centocor has brought critical biologic therapies to patients suffering from debilitating immune disorders. Centocor is a wholly-owned subsidiary of Johnson & Johnson.

CENTOCOR DISCLOSURE NOTICE: This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from Centocor's expectations and projections. Risks and uncertainties include general industry conditions and competition; economic conditions, such as interest rate and currency exchange rate fluctuations; technological advances and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approvals; domestic and foreign health care reforms and governmental laws and regulations; and trends toward health care cost containment. A further list and description of these risks, uncertainties and other factors can be found in Exhibit 99 of Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended December 30, 2007. Copies of this Form 10-K, as well as subsequent filings, are available online at, or on request from Johnson & Johnson. Centocor does not undertake to update any forward-looking statements as a result of new information or future events or developments.

About Schering-Plough

Schering-Plough is an innovation-driven, science-centered global health care company. Through its own biopharmaceutical research and collaborations with partners, Schering-Plough creates therapies that help save and improve lives around the world. The company applies its research-and-development platform to human prescription and consumer products as well as to animal health products. Schering-Plough's vision is to "Earn Trust, Every Day" with the doctors, patients, customers and other stakeholders served by its colleagues around the world. The company is based in Kenilworth, N.J., and its Web site is

SCHERING-PLOUGH DISCLOSURE NOTICE: The information in this press release includes certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the potential market for Golimumab. Forward-looking statements relate to expectations or forecasts of future events. Schering-Plough does not assume the obligation to update any forward-looking statement. Many factors could cause actual results to differ materially from Schering-Plough's forward-looking statements, including market forces, economic factors, product availability, patent and other intellectual property protection, current and future branded, generic or over-the-counter competition, the regulatory process, and any developments following regulatory approval, among other uncertainties. For further details about these and other factors that may impact the forward-looking statements, see Schering-Plough's Securities and Exchange Commission filings, including Item 8.01 of Schering-Plough's Form 8-K filed October 21, 2008.

SOURCE Centocor
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Centocor, Inc. and Schering-Plough Submit Application Requesting Approval of Golimumab in Europe for the Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
2. Medarex Receives Milestone Payment for Submission of Regulatory Application Requesting Approval of Golimumab (CNTO 148) in Europe for the Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
3. Phase 3 studies show golimumab significantly improved signs and symptoms of rheumatoid arthritis
4. One-Year Data Show Golimumab Improved Signs and Symptoms In Patients with Psoriatic Arthritis In Phase 3 Study
5. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
6. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
7. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
9. Evotec to Present Details of the Positive Phase II Study in Insomnia With EVT 201 at the Worldsleep07 Congress in Cairns/Australia
10. Phase III Trial Finds Pharmaxis Bronchitol Effective
11. YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer
Post Your Comments:
(Date:10/8/2015)... Oct. 8, 2015  Sorrento Therapeutics, Inc. (NASDAQ: ... treatments for cancer and associated pain, announced today that ... be presenting at the Aegis Capital Corporation 2015 ... :Event:Aegis Capital Corporation 2015 Growth ConferenceDate:Friday, October 9, ... Encore @ The Wynn in Las Vegas, NV ...
(Date:10/8/2015)... Celemics, a global pioneer of personalized medicine ... market with the establishment of Celemics America, Inc. ... Europe , has secured itself in the global ... sample preparation for DNA sequencing and genetic testing.  Next ... genetic testing more accurately, quickly, and cost effectively than ...
(Date:10/8/2015)... Del. , Oct. 8, 2015  Today, ... CRISPR-Cas technologies for genome editing, jointly announced a ... and Caribou have cross-licensed their respective patent portfolios, with ... technology applications in major row crops, and non-exclusive ... --> --> ...
(Date:10/8/2015)... , Oct. 8, 2015  Sigma-Aldrich Corporation ... Cerilliant ® brand within its Applied Diagnostics ... bile acid reference standards product line with ten ... routinely tested bile acids and their stable-labeled internal ... consist of lithocholic acid, taurocholic acid and native ...
Breaking Biology Technology:
... Cord Blood America, Inc. (OTC Bulletin Board: CBAI), ... ) focused on bringing the life saving ... said today that Matthew Schissler, founder and CEO, in ... Company is very close to becoming cash flow positive.The ...
... CRY ), a biomaterials, medical device and tissue processing company, ... results will be released on Thursday, February 19, 2009. ... at 10:00 a.m. Eastern Time, February 19, 2009, to discuss ... by Steven G. Anderson, president and CEO of CryoLife, Inc.To ...
... INCHEON, South Korea, Feb. 5 The Centers for ... Korean,biopharmaceutical company, have signed a Letter of Intent to ... protect people exposed to,the rabies virus. , ... rabies is a two-step procedure.,First, rabies immune globulin (RIG) ...
Cached Biology Technology:
(Date:9/30/2015)... , Sept. 30, 2015  The global glucose monitoring device ... 2015. So says a new report on the industry from ... segment dominate the market, followed by continuous glucose monitoring and ... on the market for these products in its latest report, ... , ...
(Date:9/29/2015)... 2015  iDAvatars is excited to be named one of ... market. The official announcement was recently made at an invite-only ... San Francisco , where iDAvatars presented a ... Watson. "It is both an honor and a ... bring to market the cognitive power of IBM Watson in ...
(Date:9/28/2015)... 2015  The monitoring of vital signs, such ... is an essential component of patient assessment. Changes ... in a patient,s condition. However, in general care ... taken during routine observation rounds only once every ... between these observation rounds, the warning signs can ...
Breaking Biology News(10 mins):
... it can damage blood vessels and increase the risk of ... he can thin the human blood by subjecting it to ... physics at Temple University, has pioneered the use of electric ... engines and pipelines. Now, he is using the same magnetic ...
... coastal areas in Africa can rarely utilise their entire fishing ... near the coast. Research carried out by economist Kofi Vondolia ... of fish stocks is significant to fish management. ... allows foreign fishing fleets to utilise the zones further out ...
... the Virginia Institute of Marine Science (VIMS) shows that jellyfish ... altering marine food webs by shunting food energy from fish ... frequency of jellyfish blooms in coastal and estuarine waters around ... impact on marine food webs is likely to increase into ...
Cached Biology News:
... preparation of the catalytic subunit of bovine ... isolated from the yeast Pichia pastoris to ... It recognizes the sequence Asp-Asp-Asp-Asp-Lys and cleaves ... The enzyme can be used to cleave ...
... bioassays for interferons are cytopathic effect inhibition assays, ... Sample types include; tissue culture supernatents; serum from ... assays, one unit is defined as the quantity ... cytopathic effect of viral infection by 50%. ...
Biology Products: